###### Key questions

What is already known about this subject?
=========================================

-   Non-vitamin K antagonist oral anticoagulants (NOACs) are safer and more effective than warfarin in the management of patients with atrial fibrillation (AF).

-   Globally, scientific evidence from clinical trials is compelling for NOACs use among AF patients.

-   Several NOACs have been adequately tested in large randomised clinical trials; nonetheless, most data are derived from patients enrolled from high-income countries.

What does this study add?
=========================

-   Efficacy and safety profile of dabigatran versus warfarin among patients from low-income and middle-income countries from Latin America reassuring broad NOAC applicability.

-   Consistency of results as observed in the overall findings from the main RE-LY (Randomised Evaluation of Long-Term Anticoagulant Therapy) study.

-   Potential change in regional practice (Latin America) towards improvement in the stroke and systemic embolism prevention in patients with AF.

How might this impact on clinical practice?
===========================================

-   Reassurance of consistency of efficacy/safety profile of dabigatran might lead physicians to greater use of NOAC in the management of patients with AF.

-   Due to the large stroke burden in Latin America, this information could enhance the implementation of more effective and safer treatments (NOACs) to fight stroke and related death or disabling outcomes.

-   Deliver of care by progressive and broader use of safer and more effective anticoagulants (NOACs) along with simplicity of its use in the region would be instrumental for adherence to local, regional and international guidelines.

Introduction {#s1}
============

Atrial fibrillation (AF) is responsible for \~15%--20% of all strokes.[@R1] AF occurs in 1%--2% of the population and its prevalence increases with age.[@R3] Most of the epidemiological data available for AF and related stroke predominantly are derived from patients from North America and Europe.[@R4] Although the burden of AF is high in Latin America (LA), for instance, in Brazil, \~1.5 million people have AF,[@R5] little is known about current management of AF and related stroke in developing countries. The incidence of first and recurrent strokes, intracranial and subarachnoid haemorrhages is higher in LA than in populations from North America or Europe, including non-Hispanic whites. This increased risk of stroke extends to individuals with AF from LA.[@R6] For instance, WHO estimated that nearly 2.0 million people had survived a stroke in LA in 2004, and about 25% of them experienced a first episode of stroke. Recent epidemiological data suggest a rapid increase in the incidence of strokes over the last two decades, which represents a trend seen in many Latin American nations. Furthermore, some data have shown that there is a relatively higher rate of haemorrhagic stroke in these LA countries compared with high-income nations (26% vs 9%).

Therefore, the optimal management of AF with appropriate use of oral anticoagulant therapy is of great relevance, particularly in LA. Traditionally, vitamin K antagonists (VKAs) and aspirin have been prescribed to reduce the risk of stroke in patients with AF. The use, management of care and time in therapeutic range (TTR) as an indicator of quality of oral anticoagulation with VKAs are reported to be suboptimal in South American or Latin American groups.[@R10] Nevertheless, good-quality management of AF with VKAs is still possible in deprived South American populations.[@R13]

Several non-VKA oral anticoagulants (NOACs) have been developed and tested in randomised clinical trials as alternatives to warfarin. Dabigatran etexilate (DE) is an oral direct thrombin inhibitor, and rivaroxaban, apixaban and edoxaban are direct factor Xa inhibitors.[@R14] The RE-LY (Randomised Evaluation of Long-Term Anticoagulant Therapy) trial showed that dabigatran 150 mg twice daily was more effective than warfarin for the prevention of stroke and systemic embolism (SE) in patients with AF, with similar rates of major bleeding.[@R14] In addition, dabigatran given at a dose of 110 mg twice daily was associated with similar rates of stroke and SE as compared with warfarin, as well as lower rates of major bleeding.

Patients in the RE-LY trial were recruited from a wide range of countries in terms of education, culture, income, healthcare systems and access to medications. The majority of them were enrolled in Western Europe and in the USA/Canada.[@R14] Because of this broad geographical representation, various patient characteristics and expected practice variation, regional analyses offer a unique opportunity to help further delineate the effects of dabigatran versus warfarin on patients from different geographical areas, clinical profiles and access to anticoagulant therapies. For instance, previous subanalyses of RE-LY data focusing on Japanese[@R18] and Asian populations[@R19] have observed the following: higher haemorrhagic stroke rates on warfarin in Asians versus non-Asians, despite similar blood pressure, younger age and lower international normalised ratio values; significant reduction in haemorrhagic strokes by DE in both Asians and non-Asians, demonstrating consistent benefit of DE versus warfarin across Asian and non-Asian subgroups.

Since there was a relatively large cohort of randomised patients (n=956) from LA in the RE-LY trial and the high burden of AF and related strokes in this region, we aimed to assess geographical differences in terms of efficacy and safety outcomes associated with dabigatran versus warfarin in patients with AF, specifically comparing patient data from LA and non-LA countries to evaluate potential interaction between treatment and region.

Methods {#s2}
=======

Design {#s2a}
------

This analysis was based on the phase III, prospective, randomised, open-label multinational RE-LY trial, in which 18 113 patients (951 centres in 44 countries) were randomised to two fixed doses of dabigatran (110 or 150 mg twice daily) or warfarin (target international normalised ratio (INR): 2.0--3.0) with a median follow-up of 2 years.[@R14]

Population {#s2b}
----------

Patients were considered eligible if they had a documented diagnosis of non-valvular AF (paroxysmal, persistent and permanent) and at least one additional risk factor for stroke, which included previous ischaemic stroke or transient ischaemic attack, left ventricular ejection fraction \<40%, New York Heart Association class II--IV heart failure and age ≥75 years (or age ≥65 years plus diabetes mellitus, coronary artery disease or hypertension). Reasons for exclusion were the presence of severe heart valve disorder, stroke within 14 days or severe stroke within 6 months before screening, any condition that increased the risk of haemorrhage, creatinine clearance \<30 mL/min, active liver disease, or pregnancy.

LA countries included Argentina, Brazil, Colombia, Mexico and Peru. All remaining countries included in the entire trial were considered to be non-LA countries.

Study outcomes {#s2c}
--------------

The primary outcome was the occurrence of stroke (ischaemic and haemorrhagic) or non-central nervous system systemic embolism. Other efficacy outcomes included myocardial infarction and death from any cause. The primary safety outcome was major bleeding (reduction in haemoglobin level of ≥2 g/L, transfusion of ≥2 units (U) of blood or symptomatic bleeding in a critical area or organ). Other safety outcomes were life-threatening bleeding (fatal bleeding, symptomatic intracranial haemorrhage (ICH), bleeding with a decrease in haemoglobin level of ≥5 g/L or bleeding requiring transfusion of ≥4 U of blood, inotropic agents or necessitating surgery), gastrointestinal bleeding and minor bleeding. The quality of treatment with the use of warfarin was assessed using the Rosendaal method to determine the percentage of time that the INR was in the prespecified target range: 2.0--3.0 (TTR).[@R21] All outcome events were independently adjudicated by at least two independent investigators unaware of the treatment assignments.

### Statistical analysis {#s2c1}

Baseline characteristics of patients from LA and non-LA countries were compared using t-test for continuous variables and continuity adjusted χ^2^ test for categorical variables. We developed Cox regression models to calculate HRs, CIs and p values for efficacy and safety outcomes to assess potential interaction between treatments and geographical regions. Differences in LA and non-LA mortality rates were not tested for statistical significance since it was not a priori main objective of this post hoc analysis and direct comparisons would lack statistical power to yield any major conclusion regarding mortality rates due to the different number of patients enrolled in the trial across various participating countries, which usually occur due to different timelines for site activation during the conduction of the trial. The Cox models were built after including terms for treatment, geographical region and treatment-by-region interaction. All analyses were performed using SAS software V.9.2 (SAS Institute, Cary, North Carolina, USA).

Results {#s3}
=======

Patient characteristics and management {#s3a}
--------------------------------------

A total of 956 patients from Latin America and 17 157 patients from non-LA countries were included in this analysis. The distribution of patients in LA countries was the following: Argentina (n=530), Brazil (n=249), Colombia (n=13), Mexico (n=84) and Peru (n=80). As compared with non-LA patients, patients from LA had significantly (p\<0.01) higher proportions of permanent AF (70.7% vs 33.2%), prior heart failure (41.1% vs 31.5%) and hypertension (82.3% vs 78.7%); however, age (71.6 vs 71.5), prior stroke (11.5% vs 12.6%), CHA~2~DS~2~ (2.2 vs 2.1) and CHA~2~DS~2~-VASc (3.5 vs 3.6) scores were not different. At randomisation, VKA use was lower in LA patients as compared with non-LA patients (44% vs 63%; p\<0.001); by contrast, prior aspirin use (48.4% vs 39.1%; p\<0.001) and prior ACE inhibitor use (55.9% vs 44.2%; p\<0.001) were more frequent among LA patients versus non-LA patients, respectively. Creatinine clearance was lower among LA patients (63.1 mL/min vs 73.3 mL/min; p\<0.001). Baseline characteristics are shown as online [supplementary table](#SP1){ref-type="supplementary-material"}. Moreover, the average TTR in patients on warfarin during the trial was lower in LA (n=304) than in non--LA (n=5487) patients (61.3%±22.6% vs 64.6%±19.6%; p=0.015, respectively).

10.1136/openhrt-2018-000800.supp1

Efficacy outcomes {#s3b}
-----------------

The annual rates of the primary endpoint stroke/SE were 1.47% in LA patients versus 1.45% in non-LA patients. Their annual stroke/SE rates were 0.91% versus 1.68% for dabigatran 150 mg twice daily versus warfarin, respectively (HR 0.54; 95% CI 0.18 to 1.62). The annual stroke/SE rates for dabigatran 110 mg twice daily versus warfarin were 1.82 vs 1.68, also not significantly different (HR 1.09; 95% CI 0.44 to 2.67) ([table 1](#T1){ref-type="table"} and [figure 1](#F1){ref-type="fig"}). With regards to death from any cause, HRs versus warfarin for dabigatran 110 and 150 doses were not different (0.98 LA and 0.90 non-LA, and 0.85 and 0.88, respectively). Annual mortality rates were higher 5.81% vs 3.74% among LA patients relative to non-LA patients, respectively. There were no treatment-by-region interactions for either dose of DE on all efficacy outcomes.

###### 

Efficacy outcomes with dabigatran etexilate versus warfarin in Latin American (n=956) and non-Latin American (n=17 157) patients

                                                      Dabigatran 110 mg twice daily   Dabigatran 150 mg Twice daily   Warfarin                                                                                           
  --------------------------------------------------- ------------------------------- ------------------------------- ---------------- -------- ---------------- -------- ---------------- -------- -------- ------ ---- -----
  Stroke or systemic embolism                         10                              1.09                            173              0.89     0.67             5        0.54             129      0.65     0.75   9    193
  (1.82)                                              (0.44 to 2.67)                  (1.52)                          (0.72 to 1.09)   (0.91)   (0.18 to 1.62)   (1.12)   (0.52 to 0.82)   (1.68)   (1.71)               
  Stroke                                              9                               0.98                            162              0.91     0.88             3        0.32             119      0.66     0.30   9    177
  (1.64)                                              (0.39 to 2.46)                  (1.43)                          (0.73 to 1.12)   (0.54)   (0.09 to 1.20)   (1.04)   (0.52 to 0.83)   (1.68)   (1.57)               
  Ischaemic stroke                                    9                               2.20                            143              1.09     0.25             3        0.73             100      0.75     0.97   4    130
  (1.64)                                              (0.63 to 7.14)                  (1.26)                          (0.86 to 1.39)   (0.54)   (0.16 to 3.26)   (0.87)   (0.58 to 0.98)   (0.75)   (1.15)               
  Haemorrhagic stroke                                 0                               --                              14               0.33     0.98             0        --               12       0.28     0.98   3    42
  (0.00)                                                                              (0.12)                          (0.18 to 0.60)   (0.00)                    (0.10)   (0.15 to 0.53)   (0.56)   (0.37)               
  Myocardial infarction[\*](#tblfn2){ref-type="fn"}   0                               --                              87               1.35     0.97             2        0.97             87       1.33     0.76   2    64
  (0.00)                                                                              (0.77)                          (0.98 to 1.86)   (0.36)   (0.14 to 6.90)   (0.76)   (0.97 to 1.84)   (0.37)   (0.57)               
  Death from any cause                                33                              0.98                            413              0.90     0.75             29       0.85             409      0.88     0.90   33   454
  (6.02)                                              (0.60 to 1.58)                  (3.64)                          (0.79 to 1.03)   (5.27)   (0.52 to 1.40)   (3.56)   (0.77 to 1.01)   (6.17)   (4.03)               

P values for treatment-by-region interaction are calculated by using Cox regression model with the terms for treatment, region and treatment-by-region interaction.

\*Myocardial infarction (MI) includes silent MI.

LA, Latin American.

![Efficacy outcomes with dabigatran etexilate versus warfarin in Latin American (n=956) and non-Latin American (n=17157) patients. BID, twice daily; NC, not calculable; SE, systemic embolism.](openhrt-2018-000800f01){#F1}

Safety outcomes {#s3c}
---------------

The annual rates of major bleeding were 2.63% in LA patients versus 3.28% in non-LA patients. In LA patients, the annual rates of major bleeding were 2.01% (dabigatran 110 mg twice daily) and 2.72% (dabigatran 150 mg twice daily), with relative risk reductions of 37% and 14% versus warfarin, respectively ([figure 2](#F2){ref-type="fig"} and [table 2](#T2){ref-type="table"}). In LA patients, life-threatening and total bleeding events were 31% and 24% lower with dabigatran 150 mg twice daily compared with warfarin, and 17% and 32% lower with dabigatran etexilate 110 mg twice daily compared with warfarin. ICH was 81% lower (nominally) with dabigatran 110 mg twice daily than warfarin while no LA patient on dabigatran 150 mg twice daily experienced an ICH ([figure 2](#F2){ref-type="fig"}). There were no treatment-by-region interactions for either dose of dabigatran etexilate on safety outcomes.

![Safety outcomes with dabigatran etexilate versus warfarin in Latin American (n=956) and non-Latin American (n=17157) patients. BID, twice daily; GI, gastrointestinal; NC, not calculable.](openhrt-2018-000800f02){#F2}

###### 

Safety outcomes with dabigatran etexilate versus warfarin in Latin American (n=956) and non-Latin American (n=17 157) patients

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                    Dabigatran 110 mg twice daily   Dabigatran 150 mg twice daily   Warfarin                                                                                                               
  --------------------------------- ------------------------------- ------------------------------- ---------------- ---------------- ---------------- -------- ---------------- -------- ---------------- ------ -------- --------
  Major bleeding                    11                              0.63                            331              0.81             0.52             15       0.86             384      0.94             0.81   17       404

  (2.01)                            (0.29 to 1.34)                  (2.92)                          (0.70 to 0.94)   (2.72)           (0.43 to 1.72)   (3.34)   (0.81 to 1.08)   (3.18)   (3.59)                           

  Gastrointestinal major bleeding   4                               0.65                            130              1.09             0.43             13       2.12             174      1.45             0.45   6        119

  (0.73)                            (0.18 to 2.29)                  (1.15)                          (0.85 to 1.40)   (2.36)           (0.81 to 5.58)   (1.52)   (1.15 to 1.83)   (1.12)   (1.06)                           

  Life-threatening major bleeding   6                               0.83                            141              0.66             0.68             5        0.69             174      0.81             0.80   7        211

  (1.09)                            (0.28 to 2.48)                  (1.24)                          (0.53 to 0.82)   (0.91)           (0.22 to 2.18)   (1.52)   (0.66 to 0.99)   (1.31)   (1.87)                           

  Intracranial haemorrhage          1\                              0.19\                           26\              0.30\            0.70             0\       ­--              38\      0.44\            0.98   5\       85\
                                    (0.18)                          (0.02 to 1.67)                  (0.23)           (0.19 to 0.47)                    (0.00)                    (0.33)   (0.30 to 0.64)          (0.93)   (0.75)

  Minor bleeding                    70                              0.70                            1496             0.79             0.47             76       0.77             1711     0.92             0.25   93       1838

  (12.8)                            (0.52 to 0.96)                  (13.2)                          (0.74 to 0.85)   (13.8)           (0.57 to 1.04)   (14.9)   (0.86 to 0.98)   (17.4)   (16.3)                           

  Total bleeding                    75                              0.68                            1680             0.79             0.35             83       0.76             1911     0.91             0.23   102      2064

  (13.7)                            (0.50 to 0.91)                  (14.8)                          (0.74 to 0.84)   (15.1)           (0.57 to 1.02)   (16.6)   (0.86 to 0.97)   (19.1)   (18.3)                           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

P values for treatment-by-region interaction are calculated by using Cox regression model with the terms for treatment, region and treatment-by-region interaction. The outcomes of major and intracranial haemorrhages were adjudicated by two independent investigators who were unaware of the treatment assignments.

LA, Latin American.

Discussion {#s4}
==========

Efficacy and safety of dabigatran versus warfarin {#s4a}
-------------------------------------------------

The key findings of this analysis of RE-LY are the following. First, the efficacy and safety benefits of dabigatran in LA and non-LA patients seem consistent with those shown in the RE-LY trial overall. Second, all-cause mortality was nominally around 50% higher among LA patients relative to non-LA patients. Third, TTR was lower in LA patients on warfarin therapy in the trial.

In terms of the study population clinical profile, there were some remarkable differences in the baseline characteristics, medical history and prior use of medications between LA and non-LA patients. VKA use at randomisation was lower in LA patients compared with non-LA counterparts. Moreover, a greater proportion of LA patients had hypertension, heart failure and lower creatinine clearance, which are important clinical variables that might impact on mortality and stroke risks. Moreover, permanent AF was more common among LA patients compared with non-LA patients, based on standardised definitions of type of AF. Indeed, data from the global RE-LY AF registry have shown that the greatest proportions of patients with permanent AF in emergency department settings were found in developing countries, that is, 81.4% in Africa, 54.8% in China, 52.3% in Eastern Europe and 53.4% in Brazil.[@R12] However, only a minority of those patients with AF are receiving recommended treatment with warfarin (24.3% in South America, ranging from 13.1% in China to 42.6% in North America), thus reflecting significant variations in daily practice across geographical regions. The higher incidence of stroke or SE observed in LA patients in combination with lower use of VKA enhances current knowledge of a large gap in appropriate management of care in AF setting, thus leading to great opportunity for improvement in adequate delivery of guideline-recommended AF management of care, that is, offering appropriate anticoagulation therapy when clinically indicated; increasing access to anticoagulation options of effective treatments and follow-up facilities.

The global variations in TTR and stroke risk factors aforementioned also might explain, at least in some degree, the results observed in this analysis, particularly the higher mortality risk among LA patients relative to non-LA patients. Recently developed clinical risk prediction models have also been derived from and validated in broad geographical regions, including patients from LA.[@R22]

Due to the lack of statistically significant interaction between geographical region and treatment effect, our data suggest the benefit and safety of dabigatran in comparison with warfarin for preventing stroke/SE in LA patients is consistent with the result observed in the main RE-LY trial and reassures the consistent findings from other subanalyses from other middle-income and low-income countries, such as Asian populations.[@R18]

Furthermore, we observed a lower average TTR among warfarin patients from Latin America than among their non-LA counterparts in the trial (61% vs 65%, p=0.015, respectively). More importantly, when we take the real-world data into consideration, such as the RE-LY AF registry,[@R12] the mean TTR was 46.8% in South America, ranging from 32.7% in Africa to 62.4% in Western Europe, with significant variations across geographical regions. In fact, since the desirable target of high quality of long-term anticoagulation with well-managed warfarin use has not been widely achieved, our findings are relevant for the real-world applicability and effectiveness of NOACs.

Subgroups of AF patients from LA are at increased risk of recurrent stroke compared with non-Hispanic whites.[@R6] Possible reasons that could explain this increased risk are not fully understood. Although similar CHA~2~DS~2~ and CHA~2~DS~2~-VASc scores were observed between the two geographical regions, there were greater proportions of hypertension, heart failure and impaired renal function and higher annual rates of death from any cause. Furthermore, the suboptimal use of anticoagulant therapies aforementioned and the lack of ideal TTR reflecting inadequate management of VKAs in South America and specific subgroups are likely to be contributing factors.[@R10]

The use and effectiveness of warfarin varies significantly depending on geographical region. Among patients with CHA~2~DS~2~ score ≥2, two-thirds receive appropriate antithrombotic treatment in the Middle East/Africa, while this proportion drops to 55% in Europe, 44% in Latin America and 32% in Asia.[@R23]

Finally, in our study, the rate of ICH was considerably lower in LA patients treated with dabigatran versus warfarin (ie, nominally lower rates of ICH) as observed in the main RE-LY trial. Since Hispanics have a significantly greater risk of ICH than non-Hispanic whites,[@R7] reducing the risk of ICH in this population would be of greatest benefit at the population level.

Interpretation {#s4b}
--------------

The results of this analysis adds contemporary data on clinical characteristics, management and outcomes of patients with non-valvular AF from developing countries, especially LA, emphasising key practical features: consistency of effects regardless of geographical region; more favourable efficacy and safety profile with dabigatran; and large gap in AF clinical management thus leading to great room for improvement in the prevention of stroke and/or SE among LA populations, particularly after taking into account the striking higher mortality in LA patients.

There were some differences in terms of clinical characteristics, medical history and prior use of treatments between the overall and the LA populations; however, there were no significant differences in age, prior stroke or the mean CHA~2~DS~2~ or CHA~2~DS~2~-VASc score points. The majority of LA patients had permanent AF (70.7%), while there was a roughly equal distribution of patients with permanent, paroxysmal and persistent AF in the non-LA cohort. Possible explanations for this finding include less frequent diagnosis of other types of AF and/or selection bias due to more frequent screening among permanent patients with AF with clinical evaluation, echocardiograms, liver and renal function and coagulation tests to assess eligibility for long-term anticoagulation therapy. In addition, different physician perceptions of stroke risk among various types of AF may play a role. The use of VKAs at randomisation was significantly lower in LA patients compared with non-LA patients. This is a similar trend to that seen in a previous RE-LY subanalysis of Asian (36.5%) versus non-Asian (52.0%) patients. The number of patients with previous myocardial infarction (MI) was significantly lower in LA patients (8.9%) versus non-LA patients (17.0%). This is again similar to the trend seen in previous RE-LY subanalyses; the incidence of prior MI in Asian (9.3%) and Japanese (5.5%) patients was considerably lower compared with non-Asian patients (17.9%) and the overall RE-LY population (16.6%), respectively[@R18]

Finally, the assessment of the mean time in TTR indicates less effective management of care with warfarin therapy in LA patients, thus leading to greatest benefit to be derived from NOACs and, in addition, stronger systems for administering and monitoring VKA use in daily practice also are warranted to improve the quality of care in terms of sustained oral anticoagulation.

Study strengths and limitations {#s4c}
-------------------------------

This subgroup analysis was not prespecified and there may be lack of statistical power to reliably detect differences in efficacy and safety with dabigatran versus warfarin. Nevertheless, the efficacy and safety benefits observed in the overall RE-LY trial were consistent between LA and non-LA patients, irrespective of the differences in baseline characteristics and numerical variations in the annual rates of the efficacy and safety endpoints, as compared with those seen in the entire trial population. Despite the open-label allocation of treatments in the RE-LY, all the efficacy and safety endpoints used for this analysis were ascertained during the trial and adjudicated by an independent adjudication committee who was unaware of the treatment assigned and followed standardised definition criteria. One limitation of this report was the relatively small number of LA patients (n=956) compared with non-LA counterparts (n=17 157), as already discussed in this manuscript. Other aspects to be pointed out herein include the fact that patients enrolled in randomised clinical trials usually are highly selected, especially in trials of oral anticoagulation, that is, screening for eligibility clinical criteria to be enrolled in the trial must be rigorously performed and various contraindications to receive any oral anticoagulant must be assessed, which might limit external validation (generalisability of results). In contrast, patients not selected from randomised trials ('real world practice') have more comorbidities and relatively higher risk as compared with those recruited from randomised clinical trials.

Conclusions {#s5}
===========

Despite significant differences in the clinical profiles and long-term management of care for AF between LA and non-LA patients in the RE-LY trial, the efficacy and safety benefits of dabigatran over warfarin seem consistent with those observed in the main RE-LY trial. Coupled with significant higher mortality and a lower achieved TTR indicating less effective management of care with warfarin therapy in LA patients, our data suggest that the clinical benefit from implementation of non-VKA oral anticoagulants might be of greatest benefit as compared with warfarin.
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